This study is a controlled trial of metformin in children with fragile X syndrome(FXS). The
age of FXS children range from 2 to 16 years old. Participants will be randomized in a
double-blind design to either drug or placebo for 6-month period. The primary objectives are
to assess metformin in treatment of behavior problems, cognitive and language with fragile X
syndrome.